TIPE2 and gastric neoplasm: To confirm whether TIPE2 participated in gracillin inhibition of gastric tumor cellular growth, the BGC823 and BGC823/TIPE2−/− cellular viability in the administration of gracillin (5 μM) were first examined using MTT assay.